Sarcoma  >>  Leukine (sargramostim)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

10 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Leukine (sargramostim) / Partner Therap
NCT00003408: Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer

Completed
2
40
US
aldesleukin, recombinant interferon alfa, sargramostim
Cancer Treatment Centers of America
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor
 
03/00
NCT00003955: Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Metastatic Rhabdomyosarcoma or Sarcoma

Completed
2
77
Europe, Canada, US, RoW
dactinomycin, filgrastim, pegfilgrastim, sargramostim, cyclophosphamide, irinotecan hydrochloride, vincristine sulfate, radiation therapy
Children's Oncology Group, National Cancer Institute (NCI)
Sarcoma
01/05
10/09
NCT00033644: Combination Chemotherapy Plus Sargramostim in Treating Patients With Cancer of the Uterus

Terminated
2
US, Europe
sargramostim, cisplatin, dacarbazine, doxorubicin hydrochloride, mitomycin C
Gynecologic Oncology Group, National Cancer Institute (NCI)
Sarcoma
10/05
 
NCT00652860: Combination Chemotherapy, Radiation Therapy, and Sargramostim Before and After Surgery in Treating Patients With Soft Tissue Sarcoma That Can Be Removed By Surgery

Completed
2
39
US
aerosol sargramostim, sargramostim, cisplatin, doxorubicin hydrochloride, ifosfamide, mitomycin C, flow cytometry, immunological diagnostic method, laboratory biomarker analysis, adjuvant therapy, multimodality therapy, neoadjuvant therapy, therapeutic conventional surgery, intraoperative radiation therapy, selective external radiation therapy
Mayo Clinic, National Cancer Institute (NCI)
Metastatic Cancer, Sarcoma
11/06
 
NCT00025363: Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive Rhabdomyosarcoma

Completed
2
150
US
vincristine sulfate, leurocristine sulfate, VCR, Vincasar PFS, irinotecan hydrochloride, Campto, Camptosar, CPT-11, irinotecan, U-101440E, cyclophosphamide, CPM, CTX, Cytoxan, Endoxan, Endoxana, doxorubicin hydrochloride, ADM, ADR, Adria, Adriamycin PFS, Adriamycin RDF, ifosfamide, Cyfos, Holoxan, IFF, IFX, IPP, etoposide, EPEG, VP-16, VP-16-213, tirapazamine, SR 4233, Tirazone, WIN 59075, filgrastim, G-CSF, Neupogen, sargramostim, GM-CSF, Leukine, Prokine, pharmacological study, pharmacological studies, pharmacogenomic studies, Pharmacogenomic Study, laboratory biomarker analysis
National Cancer Institute (NCI)
Alveolar Childhood Rhabdomyosarcoma, Embryonal Childhood Rhabdomyosarcoma, Embryonal-botryoid Childhood Rhabdomyosarcoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Rhabdomyosarcoma
10/07
 
COG-AOST0221, NCT00066365: Inhaled Sargramostim in Treating Patients With First Pulmonary (Lung) Recurrence of Osteosarcoma

Completed
2
49
US, Canada, RoW
sargramostim, aerosol sargramostim, inhaled GM-CSF, Granulocyte Macrophage Colony Stimulating Factor, rhu GM-CSF, rGM-CSF, GM-CSF, Prokine®, Leukine®, Interberin®, NSC#613795, conventional surgery
Children's Oncology Group, National Cancer Institute (NCI)
Metastatic Cancer, Sarcoma
07/10
12/13
NCI-2015-00694, NCT02455557: SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Active, not recruiting
2
66
US
Laboratory Biomarker Analysis, Montanide ISA 51 VG, Sargramostim, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin, SVN53-67/M57-KLH Peptide Vaccine, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac
Roswell Park Cancer Institute
Glioblastoma, Gliosarcoma
10/19
12/24
NCT02484443: Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma

Completed
2
41
Canada, US, RoW
Dinutuximab, Ch 14.18UTC, Ch14.18, Dinutuximab Beta, MOAB Ch14.18, monoclonal antibody Ch14.18, Qarziba, Unituxin, Laboratory Biomarker Analysis, Pharmacological Study, Sargramostim, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin
National Cancer Institute (NCI)
Metastatic Malignant Neoplasm in the Lung, Metastatic Osteosarcoma, Recurrent Osteosarcoma
03/20
09/23
NCT01903330: ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme

Checkmark Interim results in combination with ERC1671/GM CSF/cyclophosphamide for recurrent glioblastoma
Aug 2020 - Aug 2020: Interim results in combination with ERC1671/GM CSF/cyclophosphamide for recurrent glioblastoma
Active, not recruiting
2
84
US
ERC1671, Gliovac, GM-CSF, Leukine®, sargramostim, Cyclophosphamide, 2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate, Oral Control (Sucrose pill), Injectable control (Sodium Chloride Injection United States Pharmacopeia (USP) (0.9%)), Bevacizumab/Bevacizumab Biosimilar, Avastin, MVASI, bevacizumab-awwb, bevacizumab-bvzr, ZIRABEV
Epitopoietic Research Corporation, University of California, Irvine
Glioblastoma, Gliosarcoma
03/23
03/23
NCT02173093: Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma

Unknown status
1/2
40
US
IL-2, aldesleukin, Proleukin, recombinant human interleukin-2, recombinant interleukin-2, GD2Bi-aATC, GD2Bi-armed aATC, GM-CSF, sargramostin, Leukine, Prokine, laboratory evaluations of immune responses, laboratory biomarker analysis
University of Virginia, National Cancer Institute (NCI)
Disseminated Neuroblastoma, Recurrent Neuroblastoma
12/19
12/19

Download Options